Product Code: DMKC0131852
The pricing and reimbursement of hepatitis C therapies has been in the spotlight since the launch of Sovaldi in the US in December 2013 at the price of $1,000 per pill. While Sovaldi's and Harvoni's clinical effectiveness are undisputed, their high prices have prompted widespread criticism from payers, politicians, and patients due to the large budgetary impact of treating all eligible patients, which will exert a significant strain on healthcare systems.
This report addresses the following questions:
- What reimbursement restrictions have been imposed by US payers and how do they differ between major brands?
- Which payers have imposed patient prioritization and how do the strategies differ between countries?
- How are European payers controlling expenditure on hepatitis C drugs?
- In which markets did Sovaldi have the best outcome of the health technology assessment?
TABLE OF CONTENTS
- 1. The hepatitis C market is undergoing a seismic shift
- 2. Budgetary impact of hepatitis C therapies is causing payer pushback
- 3. Marketed hepatitis C products in the US, Japan, and five major EU markets
- 4. Pipeline hepatitis C treatments in late-stage development
- 5. Price assumptions
- 6. Bibliography
- 7. Pricing
- 8. Reimbursement
- 9. Bibliography
- 10. Price premiums are awarded for added benefit or innovation
- 11. Pricing of launched hepatitis C treatments
- 12. Treatment guidelines have been changed in the light of recent approvals
- 13. Bibliography
FIVE MAJOR EU MARKETS
- 14. Pricing
- 15. Reimbursement and health technology assessment
- 16. Bibliography